Drug news

Nektar Therapeutics announces formation of Inheris Biopharma Inc., a CNS focused company

Read time: 1 mins

Last updated:24th May 2019

Published:24th May 2019

Source: Pharmawand

Nektar Therapeutics announced the formation of Inheris Biopharma, Inc., a wholly-owned subsidiary of Nektar and a CNS-focused company. Inheris will be responsible for launch preparation and commercialization for NKTR 181, a novel, first-in-class, investigational opioid molecule.

NKTR 181 is currently under review with the FDA, with a Prescription Drug User Fee Act (PDUFA) target action date of 29 August 2019. Inheris will also lead development of several Nektar preclinical CNS assets.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

European Commission approves Bimzelx (bimekizumab) for the treatment of active moderate to severe hidradenitis suppurativa

UCB, a global biopharmaceutical company, announced that the European Commission (EC) has granted marketing authorization for Bimzelx (bimekizumab) for the treatment of active moderate to severe hidradenitis suppurativa (HS) in adults with an inadequate response to conventional systemic HS therapy

1 mins

Drug news

Voydeya approved in the EU as add-on treatment to ravulizumab or eculizumab for adults with the rare disease PNH who have residual haemolytic anaemia

Voydeya (danicopan) has been approved in the European Union (EU) as an add-on to ravulizumab or eculizumab for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who have residual haemolytic anaemia

1 min

Drug news

Subcutaneous Ocrevus one-year data from OCARINA II study demonstrates near-complete suppression of clinical relapses and brain lesions in patients with progressive and relapsing forms of MS

Roche announced data from the Phase III OCARINA II study (S31.006) of Ocrevus (ocrevuslizumab), an investigational twice-yearly, 10-minute subcutaneous (SC) injection

2 min

See all news